

Supplemental Table 1. Diagnostic yield of various endoscopic ultrasonography findings in the diagnosis of the histological subtypes of IPMN

Subject for comparison	Characteristic findings	P value	Sensitivity (95%CI)	Specificity (95%CI)	PPV (95%CI)	NPV (95%CI)	Accuracy (95%CI)
G vs. non-G	Number of cysts ≥ 2	0.0014	53% (44-58)	88% (73-95)	87% (72-95)	54% (45-59)	66% (55-72)
	Fatty parenchyma	<0.0001	63% (54-67)	92% (78-98)	92% (80-98)	61% (52-65)	74% (64-79)
	Number of cysts ≥ 2 and fatty parenchyma	0.0013	34% (27-34)	100% (89-100)	100% (80-100)	49% (44-49)	60% (51-60)
I vs. non-I	MPD diameter ≥ 10 mm	0.0011	57% (36-75)	85% (79-91)	53% (34-70)	87% (81-93)	79% (70-87)
	Cystic size < 30 mm	0.0017	86% (63-96)	50% (44-53)	33% (25-37)	92% (80-98)	58% (48-63)
	Early CP findings ≥ 2	<0.0001	86% (64-96)	83% (77-86)	60% (45-67)	95% (88-99)	83% (74-88)
	Atrophy	<0.0001	71% (50-86)	88% (81-92)	63% (44-76)	91% (85-96)	83% (74-91)
	MPD diameter ≥ 10 mm and cystic size < 30 mm	0.002	43% (24-58)	92% (86-96)	60% (34-81)	85% (80-89)	81% (72-88)
	MPD diameter ≥ 10 mm and early CP findings ≥ 2	<0.0001	43% (26-49)	98% (93-100)	86% (52-97)	86% (82-88)	86% (78-88)
	MPD diameter ≥ 10 mm and atrophy	0.0002	36% (20-42)	98% (93-100)	83% (46-97)	84% (80-85)	83% (77-87)
	Cystic size < 30 mm and early CP findings ≥ 2	<0.0001	71% (51-86)	90% (83-94)	67% (47-80)	92% (85-96)	86% (76-92)
	Cystic size < 30 mm and atrophy	<0.0001	64% (44-79)	92% (86-96)	69% (47-85)	90% (84-94)	86% (76-92)
	Early CP findings ≥ 2 and atrophy	<0.0001	57% (38-67)	96% (90-99)	80% (53-94)	88% (83-91)	87% (79-92)
	MPD diameter ≥ 10 mm, cystic size < 30 mm and early CP findings ≥ 2	0.0001	29% (15-29)	100% (96-100)	100% (54-100)	83% (80-83)	84% (78-84)
	MPD diameter ≥ 10 mm, cystic size < 30 mm and atrophy	0.0001	29% (15-29)	100% (96-100)	100% (54-100)	83% (80-83)	84% (78-84)
	MPD diameter ≥ 10 mm, early CP findings ≥ 2 and atrophy	0.0095	21% (9-27)	98% (94-100)	75% (31-95)	81% (78-82)	80% (75-83)

	Cystic size < 30 mm, early CP findings $\geq$ 2 and atrophy	<0.0001	50% (32-56)	98% (93-100)	88% (57-98)	87% (83-89)	87% (79-90)
	MPD diameter $\geq$ 10 mm, Cystic size < 30 mm, early CP findings $\geq$ 2 and atrophy	0.0078	14% (5-14)	100% (97-100)	100% (35-100)	80% (78-80)	81% (77-81)
PB vs. non-PB	None of early CP findings	0.0005	90% (63-98)	69% (64-71)	36% (25-39)	97% (90-100)	73% (64-75)
	No fatty parenchyma	0.025	90% (62-98)	48% (43-50)	25% (17-27)	96% (86-99)	55% (46-58)
	None of early CP findings and no fatty parenchyma	<0.0001	90% (66-98)	94% (90-96)	75% (55-82)	98% (93-100)	94% (86-96)

IPMN, intraductal papillary mucinous neoplasm

G, gastric

I, intestinal

PB, pancreatobiliary

CI, confidence interval

NPV, negative predictive value

PPV, positive predictive value

MPD, main pancreatic duct

CP, chronic pancreatitis

Supplemental Table 2. Relationship between EUS findings and patient characteristics

Parameter	EUS finding								
	Fatty parenchyma			Findings of early CP ≥ 2 and atrophy			None of early CP findings and no fatty parenchyma		
	presence (n = 26)	absence (n = 36)	p value	presence (n = 10)	absence (n = 52)	p value	presence (n = 12)	absence (n = 50)	p value
Age, median (IQR), years	70 (65-75)	71 (66-74)	0.95	71 (65-73)	70 (65-75)	0.98	73 (70-77)	69 (64-74)	0.13
Sex, male, n (%)	14 (54)	19 (53)	0.93	3 (30)	26 (50)	0.25	4 (33)	29 (58)	0.12
BMI, median (IQR), kg/m ²	20 (19-23)	21 (19-24)	0.66	20 (20-24)	21 (19-23)	0.76	21 (20-24)	20 (19-23)	0.51
Diabetes mellitus*, n (%)	5 (19)	13 (36)	0.15	5 (50)	13 (25)	0.11	4 (33)	14 (28)	0.71
Hypertension**, n (%)	8 (31)	14 (39)	0.51	5 (50)	17 (33)	0.29	7 (58)	15 (30)	0.07
Hyperlipidemia***, n (%)	6 (23)	7 (19)	0.73	4 (40)	9 (17)	0.11	3 (25)	10 (20)	0.7
Tobacco use, median (IQR), PY	2 (0-42)	0 (0-37)	0.62	1 (0-41)	0 (0-36)	0.94	0 (0-24)	2 (0-39)	0.2
Ethanol use, median (IQR), g/day	5 (0-20)	10 (0-20)	1	0 (0-23)	10 (0-20)	0.31	5 (0-18)	10 (0-20)	0.55
Medical history of NASH, n (%)	0 (0)	0 (0)	-	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Medical history of acute pancreatitis, n (%)	0 (0)	4 (11)	0.08	3 (30)	1 (2)	0.01	0 (0)	4 (8)	0.31
Family history of pancreatic cancer, n (%)	1 (4)	3 (8)	0.48	0 (0)	4 (8)	0.36	1 (8)	3 (6)	0.77

EUS, endoscopic ultrasonography

CP, chronic pancreatitis

IQR, interquartile range

BMI, body mass index

PY, packs/day $\times$ no. of years

NASH, nonalcoholic steatohepatitis

* Defined as hemoglobin A1c [NGSP] ≥ 6.5 .

** Defined as systolic blood pressure ≥ 140
mmHg or diastolic blood pressure ≥ 90 mmHg

*** Defined as triglycerides ≥ 150 mg/dl, low
density lipoprotein ≥ 140 mg/dl or high
density lipoprotein < 40 mg/dl